Point72 Europe (London) LLP Gilead Sciences, Inc. Transaction History
Point72 Europe (London) LLP
- $1.48 Billion
- Q3 2024
A detailed history of Point72 Europe (London) LLP transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Point72 Europe (London) LLP holds 105,397 shares of GILD stock, worth $10.2 Million. This represents 0.6% of its overall portfolio holdings.
Number of Shares
105,397
Previous 95,695
10.14%
Holding current value
$10.2 Million
Previous $6.57 Million
34.56%
% of portfolio
0.6%
Previous 0.6%
Shares
3 transactions
Others Institutions Holding GILD
# of Institutions
1,963Shares Held
995MCall Options Held
10.5MPut Options Held
9.86M-
Black Rock Inc. New York, NY121MShares$11.7 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$11.2 Billion0.18% of portfolio
-
Capital World Investors Los Angeles, CA76.5MShares$7.44 Billion1.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.8MShares$6.01 Billion1.12% of portfolio
-
State Street Corp Boston, MA60.2MShares$5.85 Billion0.21% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $122B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...